PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

September 15, 2021

Study Completion Date

December 2, 2021

Conditions
Non Small Cell Lung Cancer
Interventions
DIAGNOSTIC_TEST

89Zr-avelumab PET

89Zr-avelumab injection followed by 89Zr-Avelumab PET scan

DRUG

Avelumab

"Early stage disease (stage Ia (≥T1b tumor)-IIIa: neo-adjuvant avelumab treatment (10mg/kg iv q2w) for a maximum duration of 2 cycles after PET-imaging, followed by surgical resection of the tumor with curative intent~Stage IIIb-IV disease: systemic treatment with avelumab 10mg/kg iv q2w after PET-imaging"

Trial Locations (1)

Unknown

Radboud University, Nijmegen

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT03514719 - PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE) | Biotech Hunter | Biotech Hunter